Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials

ABSTRACT: Key Points Hyperkalemia is frequently observed in patients with CKD, and its frequency and severity increase as CKD progresses. Patiromer is an effective and well-tolerated treatment option for hyperkalemia in patients with advanced or mild/ moderate CKD on RAASi. Visual Abstract

Background

Hyperkalemia is a common electrolyte abnormality in patients with CKD, which is associated with worse outcomes and limits use of renin–angiotensin–aldosterone system inhibitors (RAASi). This post hoc subgroup analysis of three clinical trials evaluated the efficacy and safety of the sodium-free, potassium-binding polymer, patiromer, for the treatment of hyperkalemia in adults with nondialysis CKD.

Methods

Data from the 4-week treatment periods of AMETHYST-DN, OPAL-HK, and TOURMALINE s

SUBMITTER: Haller H 

PROVIDER: S-EPMC9802546 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature